

Patent Claims

1. Composition, comprising a salt of O-acetylsalicylic acid with a basic amino acid, which salt has an average particle size above a particle size of 160 μm and a proportion of more than 60% of the particles having a particle size in a range from 100 to 200 μm in a particle size distribution measured using a Malvern 2600D apparatus under standard conditions, characterized in that the composition additionally comprises a flow improver and/or is granulated.
2. Composition according to Claim 1, characterized in that it comprises, as flow improver, one or more saccharides, preferably selected from the group consisting of mannitol, sorbitol, xylitol and lactose and their mixtures.
3. Composition according to Claim 2, characterized in that it is dry-granulated, preferably roller-compacted.
4. Composition according to any of the preceding claims, characterized in that the salt has an average particle size above a particle size of 170 μm and a proportion of more than 70% of the particles having a particle size in a range from 100 to 200 μm in a particle size distribution measured using a Malvern 2600D apparatus under standard conditions.
5. Composition according to any of the preceding claims, characterized in that the basic amino acid is lysine, arginine, histidine, ornithine or diaminobutyric acid, preferably lysine.
6. Composition according to any of the preceding claims, characterized in that it additionally comprises a proportion of from 5 to 15% by weight of glycine, based on the total amount of O-acetylsalicylate and glycine.
7. Pharmaceutical, comprising at least one composition according to any of the preceding claims.

8. Pharmaceutical according to the preceding claim, characterized in that it is provided as a single-dose solid oral administration form, in particular as a tablet, a chewable tablet, a soluble tablet, an enteric-coated tablet, a capsule or a colon-targeted formulation.
9. A pharmaceutical as claimed in Claim 7 or 8, characterized in that it only comprises water-soluble auxiliaries, preferably flow improvers as set forth in Claim 2.
10. 10. Pharmaceutical according to any of Claims 7 to 9, characterized in that it is completely soluble in water.
11. 11. Pharmaceutical according to any of Claims 7 to 10, characterized in that it comprises one or more further pharmaceutically active compounds, in particular one or more ADP receptor antagonists, GPIIb/IIIa receptor antagonists, phosphodiesterase inhibitors, thrombin receptor antagonists, factor Xa inhibitors, HMG-CoA receptor antagonists and/or calcium antagonists.
12. 12. Use of compositions according to any of Claims 1 to 6 for preparing a pharmaceutical for treating disorders of a rheumatic type, arthritis, neuralgia, myalgia and/or migraine.
13. 13. Use of compositions according to any of Claims 1 to 6 for preparing a pharmaceutical for treating ischaemic heart diseases, stroke, angina pectoris, myocardial infarction, bypass operations, PTCA and/or stent implants.
14. 14. Use of compositions according to any of Claims 1 to 6 for preparing a pharmaceutical for stimulating the immune system of HIV patients, for tumour prophylaxis, for slowing down the cognitive deterioration associated with dementia, for inhibiting the formation of gallstones and/or for treating diabetic disorders.